Immunovant posted no revenue and a net loss in Q3 fiscal 2026, reflecting continued investment in research and development to advance its clinical pipeline, while maintaining a strong cash position following recent financing.

Immunovant’s Q2 2026 saw increased R&D investment driving a higher net loss, while the company preserved over $521 million in cash to support upcoming trial milestones.

Immunovant reported a Q1 2026 net loss of $120.6M, compared to $87.2M a year earlier, driven by higher expenses related to its IMVT-1402 clinical programs and personnel costs. The company ended the quarter with $598.9M in cash and equivalents, maintaining runway through 2027 for announced indications.

Immunovant reported a net loss of $106.4 million for the fourth quarter of fiscal year 2025, an increase from the $75.3 million net loss in the same period last year. This was primarily driven by increased research and development and general and administrative expenses.

Immunovant reported a net loss of $111.1 million, or $0.76 per common share, for the quarter ended December 31, 2024. As of December 31, 2024, cash and cash equivalents totaled $374.7 million.

Immunovant reported its fiscal second quarter results, highlighting the advancement of IMVT-1402 with five IND applications cleared and progress in clinical trials for batoclimab. The company is on track to initiate multiple potentially registrational trials by March 31, 2025, and anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.

Immunovant reported a net loss of $87.2 million for the quarter ended June 30, 2024. As of June 30, 2024, cash and cash equivalents totaled approximately $560 million. The company completed enrollment in the batoclimab pivotal Myasthenia Gravis (MG) trial and progressed the development of IMVT-1402.

Immunovant reported a net loss of $75.3 million for the quarter ended March 31, 2024, compared to a net loss of $59.4 million for the same period in 2023. Research and development expenses increased to $66.1 million, driven by IMVT-1402 development costs.

Immunovant reported a net loss of $51.4 million for the quarter ended December 31, 2023, with R&D expenses of $48.3 million and cash and cash equivalents totaling $691 million. The company is advancing its clinical programs for IMVT-1402 and batoclimab, with plans to initiate multiple registrational programs for IMVT-1402 and key data readouts expected from batoclimab trials in neurology in 2024.

Immunovant reported positive initial Phase 1 data for IMVT-1402 and raised $467 million in net proceeds from a public offering and private placement. The company is progressing with global clinical trials of batoclimab in myasthenia gravis (MG), thyroid eye disease (TED), and chronic inflammatory demyelinating polyneuropathy (CIDP).

Immunovant reported a net loss of $73.9 million for the quarter ended June 30, 2023. The company's cash and cash equivalents totaled $330.0 million, expected to fund operations into the second half of calendar year 2025. The company is advancing clinical trials for Batoclimab and IMVT-1402.

Immunovant reported a net loss of $59.4 million for the quarter ended March 31, 2023, with cash and cash equivalents totaling $376.5 million, expected to fund operations into the second half of calendar year 2025. Significant progress was made with IMVT-1402, including FDA clearance and initiation of a Phase 1 clinical trial.

Immunovant reported a net loss of $63.2 million for the quarter ended December 31, 2022. The company's cash and cash equivalents totaled $432.6 million as of December 31, 2022, expected to fund operations into the second half of calendar year 2025. Clinical development progressed with the initiation of Phase 3 and Phase 2b trials for batoclimab.

Immunovant reported its financial results for the second quarter ended September 30, 2022. The company unveiled IMVT-1402, a next-generation FcRn inhibitor, and announced new development programs for batoclimab in CIDP and Graves’ disease. Pro forma cash balance is expected to extend cash runway into the second half of calendar year 2025.

Immunovant reported its financial results for the first quarter ended June 30, 2022. The company's cash balance is expected to provide runway into calendar year 2025. A pivotal clinical trial of batoclimab in Myasthenia Gravis was initiated in June 2022 and alignment with the FDA was achieved on plans for two pivotal clinical trials in Thyroid Eye Disease.

Immunovant announced alignment with the FDA on Phase 3 clinical trials for batoclimab in Thyroid Eye Disease (TED) and reported financial results for the fourth quarter and fiscal year ended March 31, 2022. They are planning to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025. They had a cash balance of $493.8 million as of March 31, 2022, expected to provide cash runway into calendar year 2025.

Immunovant reported its financial results for the fiscal quarter ended December 31, 2021. The company ended the quarter with approximately $527.0 million in cash. Net loss was $41.4 million, or $0.36 per common share.

Immunovant reported a net loss of $37.7 million, or $0.35 per common share, for the quarter ended September 30, 2021. The company's research and development expenses were $21.4 million, and general and administrative expenses were $16.3 million. Immunovant ended the quarter with approximately $559 million in cash.

Immunovant reported its fiscal first quarter results with a net loss of $30.5 million, R&D expenses of $18.7 million, and G&A expenses of $11.2 million. The company ended the quarter with approximately $379 million in cash and received a $200 million strategic investment from Roivant Sciences in July 2021.

Immunovant reported a net loss of $28.2 million for the quarter ended March 31, 2021, and plans to resume clinical development of IMVT-1401 in MG and WAIHA.

Immunovant reported a net loss of $31.8 million for the quarter ended December 31, 2020, and ended the quarter with approximately $422 million in cash. The company voluntarily paused dosing in its clinical trials for IMVT-1401 due to elevated cholesterol levels.

Immunovant reported financial results for the fiscal second quarter ended September 30, 2020. The company ended the quarter with approximately $444 million in cash. Net loss was $20.8 million, or $0.25 per common share.

Immunovant reported a net loss of $26.7 million for the quarter ended June 30, 2020, and ended the quarter with approximately $280.3 million in cash.

Immunovant reported its financial results for the fiscal fourth quarter and fiscal year ended March 31, 2020. The company's cash balance as of June 29, 2020, is approximately $280.4 million. They've begun preparations to initiate a Phase 3 registrational trial of IMVT-1401 in MG.

Immunovant reported a net loss of $11.3 million and ended the quarter with $123.5 million in cash. The company also received IND clearance to initiate a Phase 2a trial in warm autoimmune hemolytic anemia (WAIHA).